Neurotrophic Enhancers as Therapy for Behavioral Deficits in Rodent Models of Huntington's Disease: Use of Gangliosides,Substituted Pyrimidines,and Mesenchymal Stem Cells
Restricted accessResearch articleFirst published online June, 2006
Neurotrophic Enhancers as Therapy for Behavioral Deficits in Rodent Models of Huntington's Disease: Use of Gangliosides,Substituted Pyrimidines,and Mesenchymal Stem Cells
The interest in using neurotrophic factors as potential treatments for neurodegenerative disorders, such as Huntington's disease, has grown in the past decade. A major impediment for the clinical utility of neurotrophic factors is their inability to cross the blood-brain barrier in therapeutically significant amounts. Although several novel mechanisms for delivering exogenous neurotrophins to the brain have been developed, most of them involve invasive procedures or present significant risks. One approach to circumventing these problems is using therapeutic agents that can be administered systemically and have the ability to enhance the activity of neurotrophic factors. This review highlights the use of gangliosides, substituted pyrimidines, and mesenchymal stem cells as neurotrophic enhancers that have significant therapeutic potential while avoiding the pitfalls of delivering exogenous neurotrophic factors through the blood-brain barrier. The review focuses on the potential of these neurotrophic enhancers for treating the behavioral deficits in rodent models of Huntington's disease.
Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Do, J., et al. (2001). Transgenic mice with an expanded CAG repeat controlled by the human AR promoter show polyglutamine nuclear inclusions and neuronal dysfunction without neuronal cell death. Human Molecular Genetics, 10, 1039-1048.
2.
Akiyama, Y., Radtke, C., & Kocsis, J. D. (2002). Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. Journal of Neuroscience, 22, 6623-6630.
3.
Alleva, E., & Santucci, D. (2001). Psychosocial versus “physical” stress situations in rodents and humans: Role of neurotrophins. Physiology & Behavior, 73, 313-320.
4.
Altar, C. A., Cai, N., Bliven, T., Juhasz, M., Conner, J. M., Acheson, A. L., et al. (1997). Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature, 389, 856-860.
5.
Anderson, K. D., Panayotatos, N., Corcoran, T. L., Lindsay, R. M., & Wiegand, S. J. (1996). Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America, 93, 7346-7351.
6.
Awaya, A., Kobayashi, H., Horikomi, K., Tanaka, S., Kabir, A. M., Yokoyama, K., et al. (1993). Neurotrophic pyrimidine heterocyclic compounds I: The newly synthesized pyrimidine compounds promote neurite outgrowth of GOTO and neuro 2a neuroblastoma cell lines, and potentiate nerve growth factor-induced neurite sprouting of PC12 cells. Biological and Phamacological Bulletin, 16, 248-253.
7.
Azizi, S. A., Stokes, D., Augelli, B. J., DiGirolamo, C., & Prockop, D. J. (1998). Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats—Similarities to astrocyte grafts. Proceedings of the National Academy of Sciences of the United States of America, 95, 3908-3913.
8.
Baquet, Z. C., Gorski, J. A., & Jones, K. R. (2004). Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. Journal of Neuroscience, 24, 4250-4258.
9.
Barry, F. P., & Murphy, J. M. (2004). Mesenchymal stem cells: Clinical applications and biological characterization. International Journal of Biochemistry and Cellular Biology, 36, 568-584.
10.
Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J. M., et al. (1993). Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. Journal of Neuroscience, 13, 4181-4192.
11.
Beal, M. F., Ferrante, R. J., Swartz, K. J., & Kowall, N. W. (1991). Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. Journal of Neuroscience, 11, 1649-1659.
12.
Bennett, M. R. (1983). Development of neuromuscular synapses. Physiological Reviews, 63, 915-1048.
13.
Bizon, J. L., Lauterborn, J. C., & Gall, C. M. (1999). Subpopulations of striatal interneurons can be distinguished on the basis of neurotrophic factor expression. Journal of Comparative Neurology, 408, 283-298.
14.
Bjornson, C. R., Rietze, R. L., Reynolds, B. A., Magli, M. C., & Vescovi, A. L. (1999). Turning brain into blood: A hematopoietic fate adopted by adult neural stem cells in vivo. Science, 283, 534-537.
15.
Borison, R. L., & Diamond, B. I. (1979). Kainic acid animal model predicts therapeutic agents in Huntington's chorea. Transactions of the American Neurological Association, 104, 67-69.
16.
Borlongan, C. V., Koutouzis, T. K., & Sanberg, P. R. (1997). 3-Nitroproprionic acid animal model and Huntington's disease. Neuroscience & Biobehavioral Reviews, 21, 289-293.
17.
Bottjer, S. W. (2002). Neural strategies for learning during sensitive periods of development. Journal of Comparative Physiology A: Neuroethology, Sensory, Neural, and Behavioral Physiology, 188, 917-928.
18.
Bradbury, E. J., Kershaw, T. R., Marchbanks, R. M., & Sinden, J. D. (1995). Astrocyte transplants alleviate lesion induced memory deficits independently of cholinergic recovery. Neuroscience, 65, 955-972.
19.
Brazelton, T. R., Rossi, F. M., Keshet, G. I., & Blau, H. M. (2000). From marrow to brain: Expression of neuronal phenotypes in adult mice. Science, 290, 1775-1779.
20.
Brederlau, A., Correia, A. S., Anisimov, S. V., Elmi, M., Roybon, L., Paul, G., et al. (2006). Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson's disease: Effect of in vitro differentiation on graft survival and teratoma formation. Stem Cell. Retrieved March 23, 2006, from http://stemcells.alphamedpress.org/cgi/content/abstract/2005-0393v1
21.
Buck, C. R., Martinez, H. J., Chao, M. V., & Black, I. B. (1988). Differential expression of nerve growth factor receptor gene in multiple brain areas. Developmental Brain Research, 44, 259-268.
22.
Bueker, E. D. (1948). Implantation of tumors in the hindlimb field of the embryonic chick and developmental response of the lumbosacral nervous system. Anatomical Record, 102, 369-390.
23.
Calamandrei, G., & Alleva, E. (1995). Neuronal growth factors, neurotrophins, and memory deficiency. Behavioral Brain Research, 66, 129-132.
24.
Canals, J. M., Checa, N., Marco, S., Akerud, P., Michels, A., Perez-Navarro, E., et al. (2001). Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area. Journal of Neuroscience, 21, 117-124.
25.
Cancedda, L., Putignano, E., Sale, A., Viegi, A., Berardi, N., & Maffei, L. (2004). Acceleration of visual system development by environmental enrichment. Journal of Neuroscience, 24, 4840-4848.
26.
Carbonetto, S., Gruver, M. M., & Turner, D. C. (1983). Nerve fiber growth in culture on fibronectin, collagen, and glycosaminoglycan substrates. Journal of Neuroscience, 3, 2324-2335.
27.
Chao, M. V. (2003). Neurotrophins and their receptors: A convergence point for many signaling pathways. Nature Reviews Neuroscience, 4, 299-309.
28.
Chun, H. S., Yoo, M. S., DeGiorgio, L. A., Volpe, B. T., Peng, D., Baker, H., et al. (2002). Marked dopaminergic cell loss subsequent to developmental, intranigral expression of glial cell line-derived neurotrophic factor. Experimental Neurology, 173, 235-244.
29.
Chunmeng, S., Tianmin, C., Yongping, S., Xinze, R., Yue, M., Jifu, Q., et al. (2004). Effects of dermal multipotent cell transplantation on skin wound healing. Journal of Surgical Research, 121, 13-19.
30.
Cogle, C. R., Yachnis, A. T., Laywell, E. D., Zander, D. S., Wingard, J. R., Steindler, D. A., et al. (2004). Bone marrow transdifferentiation in brain after transplantation: A retrospective study. The Lancet, 363, 1432-1437.
31.
Cohen-Cory, S. (2002). The developing synapse: Construction and modulation of synaptic structures and circuits. Science, 298, 770-776.
32.
Condorelli, D. F., Dell'Albani, P., Mudo, G., Timmusk, T., & Belluardo, N. (1994). Expression of neurotrophins and their receptors in primary astroglial cultures: Induction by cyclic AMP-elevating agents. Journal of Neurochemistry, 62, 509-516.
33.
Coyle, J. T. (1979). An animal model for Huntington's disease. Biological Psychiatry, 14, 251-276.
34.
Croll, S. D., Suri, C., Compton, D. L., Simmons, M. V., Yancopoulos, G. D., Lindsay, R. M., et al. (1999). Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity, and in-vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience, 93, 1491-1506.
35.
Dallner, C., Woods, A. G., Deller, T., Kirsch, M., & Hoffman, H. D. (2002). CNTF and CNTF receptor alpha are constitutively expressed by astrocytes in the mouse brain. Glia, 37, 374-378.
36.
Das, K. P., Chao, S. L., White, L. D., Haines, W. T., Harry, G. J., Tilson, H. A., et al. (2001). Differential patterns of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 mRNA and protein levels in developing regions of the rat brain. Neuroscience, 103, 739-761.
37.
de Almeida, L. P., Zala, D., Aebischer, P., & Deglon, N. (2001). Neuroprotective effect of a CNTF-expressing lentiviral vector in the quinolinic acid rat model of Huntington's disease. Neurobiology of Disease, 8, 433-446.
38.
DeKosky, S. T., & Marek, K. (2003). Looking backward to move forward: Early detection of neurodegenerative disorders. Science, 302, 830-834.
39.
Denkins, Y., Reiland, J., Roy, M., Sinnappah-Kang, N. D., Galjour, J., Murray, B. P., et al. (2004). Brain metastasis in melanoma: Roles of neurotrophins. Neuro-Oncology, 6, 154-165.
40.
Djouad, F., Plence, P., Bony, C., Tropel, P., Apparailly, F., Sany, J., et al. (2003). Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood, 102, 3837-3844.
41.
Dormady, S. P., Bashayan, O., Dougherty, R., Zhang, X. M., & Basch, R. S. (2001). Immortalized multipotential mesenchymal cells and the hematopoietic microenvironment. Journal of Hematotherapy and Stem Cell Research, 10, 125-140.
42.
Duchemin, A. M., Neff, N. H., & Hadjiconstantinou, M. (1997). GM1 increases the content and mRNA of NGF in the brain of aged rats. NeuroReport, 8, 3823-3827.
43.
Dunbar, G. L., Butler, W., Fass, B., & Stein, D. G. (1986). Behavioral and neurochemical alterations by exogenous gangliosides in brain-damaged animals: Problems and perspectives. In G. Tettamanti, R. Ledeen, K. Sandhoff, Y. Nagai, & G. Toffano (Eds.), Gangliosides and neuronal plasticity(pp. 365-380). Padova, Italy: Liviana Press.
44.
Dunbar, G. L., Hecht, S. A., Merbaum, S. L., DeAngelis, M. M., & Stein, D. G. (1987). Use of gangliosides and amphetamine to promote behavioral recovery following bilateral caudate nucleus lesions. In R. L. Masland, A. Portera-Sanchez, & G. Toffano (Eds.), Neuroplasticity: A new therapeutical tool in the CNS pathology (pp. 117-124). Padova, Italy: Liviana Press.
45.
Dunbar, G. L., Lescaudron, L. L., & Stein, D. G. (1993). Comparison of GM1 ganglioside, AGF2, and d-amphetamine as treatments for spatial reversal and place learning deficits following lesions of the neostriatum. Behavioural Brain Research, 54, 67-79.
46.
Dunbar, G. L., Oh-Lee, J., & Lescaudron, L. (2006). Use of bone marrow stem cells as therapy for behavioral deficits in rodent models of Huntington's disease. In P. R. Davis & C. D. Sanberg (Eds.), Contemporary neuroscience: Cell therapy for brain repair (pp. 117-138). Totowa, NJ: Humana Press.
47.
Dunbar, G. L., Shear, D. A., Dong, J., & Haik-Creguer, K. L. (1999). Cognitive and motor deficits produced by acute and chronic administration of 3-nitropropionic acid in rats. In P. R. Sanberg, H. Nishino, & C. V. Borlongan (Eds.), Mitochondrial inhibitors and neurodegenerative disorders (pp. 73-92). Totowa, NJ: Humana Press.
48.
Dunbar, G. L., & Stein, D. G. (1988). The use of ganglioside as a pharmacological treatment for behavioral deficits following CNS injury. In B. A. Sabel and D. G. Stein (Eds.), Pharmacological approaches to treatment of brain and spinal cord injury(pp. 195-218). New York: Plenum.
49.
Eaves, C. J., Cashman, J. D., Kay, R. J., Dougherty, G. J., Otsuka, T., Gaboury, L. A., et al. (1991). Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood, 78, 110-117.
50.
Eglitis, M. A., & Mezey, E. (1997). Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proceedings of the National Academy of Sciences of the United States of America, 94, 4080-4085.
51.
English, A. W. (2003). Cytokines, growth factors and sprouting at the neuromuscular junction. Journal of Neurocytology, 32, 943-960.
52.
Emerich, D. F., Hammang, J. P., Baetge, E. E., & Winn, S. R. (1994). Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum. Experimental Neurology, 130, 141-150.
53.
Emerich, D. F., & Winn, S. R. (2004). Neuroprotective effects of encapsulated CNTF-producing cells in a rodent model of Huntington's disease are dependent on the proximity of the implant to the lesioned striatum. Cell Transplantation, 13, 253-259.
54.
Enna, S. J. (1977). Neurobiology and pharmacology of Huntington's disease. Life Sciences, 20, 205-211.
55.
Ferrante, R. J., Kowall, N. W., Beal, M. F., Martin, J. B., Bird, E. D., & Richardson, E. P., Jr. (1987). Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. Journal of Neuropathology and Experimental Neurology, 46, 12-27.
56.
Ferrante, R. J., Kowall, N. W., Cipolloni, P. B., Storey, E., & Beal, M. F. (1993). Excitotoxin lesions in primates as a model for Huntington's disease: Histopathologic and neurochemical characterization. Experimental Neurology, 119, 46-71.
57.
Ferrari, G., Anderson, B. L., Stephens, R. M., Kaplan, D. R., & Greene, L. A. (1995). Prevention of apoptotic neuronal death by GM1 ganglioside: Involvement of Trk neurotrophin receptors. Journal of Biological Chemistry, 270, 3074-3080.
58.
Figueredo-Cardenas, G., Anderson, K. D., Chen, Q., Veenman, C. L, & Reiner, A. (1994). Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Experimental Neurology, 129, 37-56.
59.
Friedenstein, A. J., Chailakhyan, R. K., Latsinik, N. V., Panasyuk, A. F., & Keiliss-Borok, I. V. (1974). Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: Cloning in vitro and retransplantation in vivo. Transplantation, 17, 331-340.
60.
Frim, D. M., Short, M. P., Rosenberg, W. S., Simpson, J., Breakefield, X. O., & Isacson, O. (1993). Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum. Journal of Neurosurgery, 78, 267-273.
61.
Fyfe, J. A., Beauchamp, L. M., Caggiano, A., Price, R. D., Takayuki, Y., Matsuoka, N., et al. (2004). KP544 amplifies the effects of nerve growth factors on cell differentiation and is neuroprotective. Drug Development Research, 62, 49-59.
62.
Galli, R., Gritti, A., Bonfanti, L., & Vescovi, A. L. (2003). Neural stem cells: An overview. Circulation Research, 92, 598-608.
63.
Garcia, M., Vanhoutte, P., Pages, C., Besson, M., Brouillet, E., & Caboche, J. (2002). The mitochondrial toxin 3-nitropropionic acid induces striatal neurodegeneration via a c-jun N-terminal kinase/c-jun module. Journal of Neuroscience, 22, 2174-2184.
64.
Gardian, G., & Vecsei, L. (2004). Huntington's disease: Pathomechanism and therapeutic perspectives. Journal of Neural Transmission, 111, 1485-1494.
65.
Gauthier, L. R., Charrin, B. C., Borrell-Pages, M., Dompierre, J. P., Rangone, H., Cordelieres, F. P., et al. (2004). Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell, 118, 127-138.
66.
Georgiou-Karistianis, N., Smith, E., Bradshaw, J. L., Chua, P., Lloyd, J., Churchyard, A., et al. (2003). Future directions in research with presymptomatic individuals carrying the gene for Huntington's disease. Brain Research Bulletin, 59, 331-338.
67.
Gibbons, A., Wreford, N., Pankhurst, J., & Bailey, K. (2005). Continuous supply of the neurotrophins BDNF and NT-3 improve chick motor neuron survival in vivo. International Journal of Developmental Neuroscience, 23, 389-396.
68.
Glosser, G. (2001). Neurobehavioral aspects of movement disorders. Neurologic Clinics, 19, 535-551.
69.
Gomide, V., & Chadi, G. (2005). Glial bFGF and S100 immunoreactivities increase in ascending dopamine pathways following striatal 6-OHDA-induced partial lesion of the nigrostriatal system: A sterological analysis. International Journal of Neuroscience, 115, 537-555.
70.
Grosse, G., Djalali, S., Deng, D. R., Holtje, M., Schwartzkopff, K., Cygon, M., et al. (2005). Area-specific effects of brain-derived neurotrophic factor (BDNF) genetic ablation on various neuronal subtypes of the mouse brain. Developmental Brain Research, 156, 111-126.
71.
Gu, X., Li, C., Wei, W., Lo, V., Gong, S., Li, S.-H., et al. (2005). Pathological cell-cell interactions elicited by a neuropathogenic form of mutant huntingtin contribute to cortical pathogenesis in HD mice. Neuron, 46, 433-444.
72.
Haik, K. L., Shear, D. A., Schroeder, U., Sabel, B. A., & Dunbar, G. L. (2000). Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease. Experimental Neurology, 163, 430-439.
73.
Hanamura, K., Harada, A., Katoh-Semba, R., Murakami, F., & Yamamoto, N. (2004). BDNF and NT-3 promote thalamocortical axon growth with distinct substrate and temporal dependency. European Journal of Neuroscience, 19, 1485-1493.
74.
Hart, T., Chaimas, N., Moore, R. Y., & Stein, D. G. (1978). Effects of nerve growth factor on behavioral recovery following caudate nucleus lesions in rats. Brain Research Bulletin, 3, 245-250.
75.
Haynesworth, S. E., Baber, M. A., & Caplan, A. I. (1996). Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: Effects of dexamethasone and IL-1 alpha. Journal of Cellular Physiology, 166, 585-592.
76.
Hedreen, J. C., & Folstein, S. E. (1995). Early loss of neostriatal strio-some neurons in Huntington's disease. Journal of Neuropathology and Experimental Neurology, 54, 105-120.
77.
Hensch, T. K. (2004). Critical period regulation. Annual Review of Neuroscience, 27, 549-579.
78.
Ho, L. W., Carmichael, J., Swartz, J., Wyttenbach, A., Rankin, J., & Rubinsztein, D. C. (2001). The molecular biology of Huntington's disease. Psychological Medicine, 31, 3-14.
79.
Hobbs, S. H., & Spiegel, K. (1991). U.S. Patent No. 5,075,305. Washington, DC: U.S. Patent and Trademark Office.
80.
Hodgson, J. G., Agopyan, N., Gutekunst, C. A., Leavitt, B. R., LePiane, F., Singaraja, R., et al. (1999). A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron, 23, 181-192.
81.
Huang, L., Guo, H., Hellard, D. T., & Katz, D. M. (2005). Glial cell line-derived neurotrophic factor (GDNF) is required for differentiation of pontine noradrenergic neurons and patterning of central respiratory output. Neuroscience, 130, 95-105.
82.
Jiang, B., Akaneya, Y., Ohsima, M., Ichisaka, S., Hata, Y., & Tsumoto, T. (2001). Brain derived neurotrophic factor induces long-lasting potentiation of synaptic transmission in visual cortex in vivo in young rats, but not in the adult. European Journal of Neuroscience, 14, 1219-1228.
83.
Jin, H. K., Carter, J. E., Huntley, G. W., & Schuchman, E. H. (2002). Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. Journal of Clinical Investigation, 109, 1183-1191.
84.
Jin, K., LaFevre-Bernt, M., Sun, Y., Chen, S., Gafni, J., Crippen, D., et al. (2005). FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America, 102, 18189-18194.
85.
Johnson, J., & Oppenheim, R. (1994). Keeping track of changing neurotrophic theory. Current Biology, 4, 662-665.
86.
Keller-Peck, C. R., Feng, G., Sanes, J. R., Yan, Q., Lichtman, J. W., & Snider, W. D. (2001). Glial cell line-derived neurotrophic factor administration in postnatal life results in motor unit enlargement and continuous synaptic remodeling at the neuromuscular junction. Journal of Neuroscience, 21, 6136-6146.
87.
Kells, A. P., Fong, D. M., Dragunow, M., During, M. J., Young, D., & Connor, B. (2004). AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington's disease. Journal of the American Society of Gene Therapy, 9, 682-688.
88.
Kojima, M., Klein, R. L., & Hatanaka, H. (2002). Pre- and post-synaptic modification by neurotrophins. Neuroscience Research, 43, 193-199.
89.
Kordower, J. H., Isacson, O., & Emerich, D. F. (1999). Cellular delivery of trophic factors for the treatment of Huntington's disease: Is neuroprotection possible?Experimental Neurology, 159, 4-20.
90.
Kordower, J. H., Vinod, C., Bayer, R., Bartus, R. T., Putney, S., Walus, L. R., et al. (1994). Intravenous administration of a transferring receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proceedings of the National Academy of Science of the United States of America, 91, 9077-9080.
91.
Krieglstein, K. (2004). Factors promoting survival of mesencephalic dopaminergic neurons. Cell & Tissue Research, 318, 73-80.
92.
Krenitsky, T. A., Dillinger, J., Zotova, E., Arezzo, J. C., Koprich, J. B., Mortazavi, F., et al. (2004). KP544, a nerve growth factor amplifier: Pharmacokinetics, safety, and efficacy in the rat. Drug Development Research, 62, 60-70.
93.
Kurozumi, K., Nakamura, K., Tamiya, T., Kawano, Y., Ishii, K., Kobune, M., et al. (2005). Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Molecular Therapy, 11, 96-104.
94.
Largaespada, D. A., & Verfaillie, C. M. (2000). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature, 418, 41-49.
95.
Lee, R., Kermani, P., Teng, K. K., & Hempstead, B. L. (2001). Regulation of cell survival by secreted proneurotrophins. Science, 294, 1945-1948.
96.
Lehmann, S., Quirosa-Guillou, C., Becherer, U., Thal, C., & Zanetta, J. P. (1993). Neurite outgrowth of neurons of rat dorsal root ganglion induced by new neurotrophic substances with guanidine group. Neuroscience Letters, 152, 57-60.
97.
Lescaudron, L., Fulop, Z., Sutton, R. L., Geller, H. M., & Stein, D. G. (2001). Behavioral and morphological consequences of primary astrocytes transplanted into the rat cortex immediately after nucleus basalis ibotenic lesion. International Journal of Neuroscience, 106, 63-85.
98.
Lescaudron, L., Unni, D., & Dunbar, G. L. (2003). Autologous adult bone marrow stem cell transplantation in an animal model of Huntington's disease: Behavioral and morphological outcomes. International Journal of Neuroscience, 113, 945-956.
99.
Lessmann, V., Gottmann, K., & Heumann, R. (1994). BDNF and NT-4/5 enhance glutamatergic synaptic transmission in cultured hippocampal neurons. NeuroReport, 6, 21-25.
100.
Levi-Montalcini, R. (1952). Effects of mouse tumor transplantation on the nervous system. Annals of the New York Academy of Sciences, 55, 330-343.
101.
Levy, Y. S., Gilgun-Sherki, Y., Melamed, E., & Offen, D. (2005). Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs, 19, 97-127.
102.
Li, J., Ding, Y. H., Rafols, J. A., Lai, Q., McAllister, J. P., II, & Ding, Y. (2005). Increased astrocyte proliferation in rats after running exercise. Neuroscience Letters, 386, 160-164.
103.
Li, Y., Chen, J., Chen, X. G., Wang, L., Gautam, S. C., Xu, Y. X., et al. (2002). Human marrow stromal cell therapy for stroke in rat: Neurotrophins and functional recovery. Neurology, 59, 514-523.
104.
Lin, Q., Cunningham, L. A., Epstein, L. G., Pechan, P. A., Short, M. P., Fleet, C., et al. (1997). Human fetal astrocytes as an ex vivo gene therapy vehicle for delivering biologically active nerve growth factor. Human Gene Therapy, 8, 331-339.
105.
Liu, H., Iacono, R. P., & Szalay, A. A. (2001). Detection of GDNF secretion in glial cell culture and from transformed cell implants in the brains of live animals. Molecular Genetics & Genomics, 266, 614-623.
106.
Lloyd, K. G. (1980). The neuropathology of GABA neurons in extrapyramidal disorders. Journal of Neural Transmission Supplement, 16, 217-227.
107.
Longhi, L., Zanier, E. R., Royo, N., Stocchetti, N., & McIntosh, T. K. (2005). Stem cell transplantation as a therapeutic strategy for traumatic brain injury. Transplantation and Immunology, 15, 143-148.
108.
Lu, B. (2003). Pro-region of neurotrophins: Role in synaptic modulation. Neuron, 39, 735-738.
109.
Lu, B., & Je, H. S. (2003). Neurotrophic regulation of the development and function of the neuromuscular synapses. Journal of Neurocytology, 32, 931-941.
110.
Lu, L., Zhao, C., Liu, Y., Sun, X., Duan, C., Ji, M., et al. (2005). Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Brain Research Protocols, 15, 46-51.
111.
Ludolph, A. C., He, F., Spencer, P. S., Hammerstad, J., & Sabri, M. (1991). 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Canadian Journal of Neurological Sciences, 18, 492-498.
112.
Madhavan, L., Ourednik, V., & Ourednik, J. (2005). Grafted neural stem cells shield the host environment from oxidative stress. Annals of the New York Academy of Sciences, 1049, 185-188.
113.
Majumdar, M. K., Thiede, M. A., Mosca, J. D., Moorman, M., & Gerson, S. L. (1998). Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. Journal of Cellular Physiology, 176, 57-66.
114.
Makwana, M., & Raivich, G. (2005). Molecular mechanisms in successful peripheral regeneration. Federation of European Biochemical Societies Journal, 272, 2628-2638.
115.
Marotte, L. R., Vidovic, M., Wheeler, E., & Jhaveri, S. (2004). Brain-derived neurotrophic factor is expressed in a gradient in the superior colliculus during development of the retinocollicular projection. European Journal of Neuroscience, 20, 843-847.
116.
Martin, C., Melchior, B., Nerriere-Daguin, V., Naveilhan, P., Soulillou, J.-P., & Brachet, P. (2005). Beta1 integrin as a xenoantigen in fetal porcine mesencephalic cells transplanted into the rat brain. Cell Transplantation, 14, 527-536.
117.
Matsunaga, W., Shirokawa, T., & Isobe, K. (2004). BDNF is necessary for maintenance of noradrenergic innervations in the aged rat brain. Neurobiology of Aging, 25, 341-348.
118.
McAllister, A. K. (2002). Neurotrophins and cortical development. Results & Problems in Cell Differentiation, 39, 89-112.
119.
Mendell, L. M., Albers, K. M., & Davis, B. M. (1999). Neurotrophins, nociceptors, and pain. Microscopy Research & Technique, 45, 252-261.
120.
Menei, P., Pean, J. M., Narrier-Daguin, V., Jollivet, C., Brachet, P., & Benoit, P. (2000). Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage. Experimental Neurology, 161, 259-272.
121.
Mezey, E., Chandross, K. J., Harta, G., Maki, R. A., & McKercher, S. R. (2000). Turning blood into brain: Cells bearing neuronal antigens generated in vivo from bone marrow. Science, 290, 1779-1782.
122.
Miranda, R. C., Sohrabji, F., & Toran-Allerand, C. D. (1993). Neuronal colocalization of mRNAs for neurotrophins and their receptors in the developing central nervous system suggests a potential for autocrine interactions. Proceedings of the National Academy of Sciences of the United States of America, 90, 6439-6443.
123.
Miura, M., Gronthos, S., Zhao, M., Lu, B., Fisher, L. W., Robey, P. G., et al. (2003). SHED: Stem cells from human exfoliated deciduous teeth. Proceedings of the National Academy of Sciences of the United States of America, 100, 5807-5812.
124.
Mobley, W. C., Woo, J. E., Edwards, R. H., Riopelle, R. J., Longo, F. M., Weskamp, G., et al. (1989). Developmental regulation of the nerve growth factor receptor gene in multiple brain areas. Developmental Brain Research, 44, 259-268.
125.
Mocchetti, I. (2005). Exogenous gangliosides, neuronal plasticity and repair, and the neurotrophins. Cellular and Molecular Life Sciences, 62, 2283-2294.
126.
Moretto, G., Xu, R. Y., Walker, D. G., & Kim, S. U. (1994). Co-expression of mRNA for neurotrophic factors in human neurons and glial cells in culture. Journal of Neuropathology & Experimental Neurology, 53, 78-85.
127.
Mutoh, T., Tokuda, A., Miyadai, T., Hamaguchi, M., & Fujiki, N. (1995). Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proceedings of the National Academy of Sciences of the United States of America, 92, 5087-5091.
128.
Nagano, M., & Suzuki, H. (2003). Quantitative analysis of expression of GDNF and neurotrophins during postnatal development in rat skeletal muscles. Neuroscience Research, 45, 391-399.
129.
Nguyen, Q. T., Parsadanian, A. S., Snider, W. D., & Lichtman, J. W. (1998). Hyperinnervation of neuromuscular junctions caused by GDNF overexpression in muscle. Science, 279, 1725-1729.
130.
Nicolson, G. L., Menter, D. G., Herrmann, J., Cavanaugh, P., Jia, L., Hamada, J., et al. (1994). Tumor metastasis to brain: Role of endothelial cells, neurotrophins, and paracrine growth factors. Critical Reviews in Oncogenesis, 5, 451-471.
131.
Nomura, T., Honmou, O., Harada, K., Houkin, K., Hamada, H., & Kocsis, J. D. (2005). I.V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience, 136, 161-169.
132.
Nosheny, R. L., Bachis, A., Acquas, E., & Mocchetti, I. (2004). Human immunodeficiency virus type 1 glycoprotein gp120 reduces the levels of brain-derived neurotrophic factor in vivo: potential implications for neuronal cell death. European Journal of Neuroscience, 20, 2857-2864.
133.
Oelmann, E., Sreter, L., Schuller, I., Serve, H., Koenigsmann, M., Weidenmann, B., et al. (1995). Nerve growth factor stimulates clonal growth of human lung cancer cell lines and human glioblastoma cell line expressing high affinity nerve growth factor binding sites involving tyrosine kinase signaling. Cancer Research, 55, 2212-2219.
134.
Oo, T. F., Ries, V., Cho, J., Kholodilov, N., & Burke, R. E. (2005). Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during post-natal development of the rat. Journal of Comparative Neurology, 484, 57-67.
135.
Park, D. S., Morris, E. J., Stafanis, L., Troy, C. M., Shelanski, M. L., Geller, H. M., et al. (1998). Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. Journal of Neuroscience, 18, 830-840.
136.
Park, K. W., Eglitis, M. A., & Mouradian, M. M. (2001). Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neuroscience Research, 40, 315-323.
137.
Paxinos, G., & Watson, C. (1997). The rat brain in stereotaxic coordinates (3rd ed.). San Diego, CA: Academic Press.
138.
Perez-Navarro, E., Alberch, J., Arenas, E., Calvo, N., & Marsal, J. (1994). Nerve growth factor and basic fibroblast growth factor protect cholinergic neurons against quinolinic acid excitotoxicity in rat neostriatum. European Journal of Neuroscience, 6, 706-711.
139.
Perez-Navarro, E., Canudas, A. M., Akerund, P., Alberch, J., & Arenas, E. (2000). Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4/5 prevent cell death of striatal projection neurons in a rodent model of Huntington's disease. Journal of Neurochemistry, 75, 2190-2199.
140.
Pietropaolo, S., Branchi, I., Cirulli, F., Chiarotti, F., Aloe, L., & Alleva, E. (2004). Long-term effects of the periadolescent environment on exploratory activity and aggressive behavior in mice: Social versus physical environment. Physiology & Behavior, 81, 443-453.
141.
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143-147.
142.
Portera-Cailliau, C., Hedreen, J. C., Price, D. L., & Koliatsos, V. E. (1995). Evidence for apoptotic cell death in Huntington's disease and excitotoxic animal models. Journal of Neuroscience, 15, 3775-3787.
143.
Popovic, N., Maingay, M., Kirik, D., & Brundin, P. (2005). Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Experimental Neurology, 193, 65-74.
144.
Purves, D., &Lichtman, J. W. (1980). Elimination of synapses in the developing nervous system. Science, 210, 153-157.
145.
Rabin, S. J., Bachis, A., & Mocchetti, I. (2002). Gangliosides activate Trk receptors by inducing the release of neurotrophins. Journal of Biological Chemistry, 277, 49466-49472.
146.
Rabin, S. J., & Mocchetti, I. (1995). GM1 ganglioside activates the high-affinity nerve growth factor receptor trkA. Journal of Neurochemistry, 65, 347-354.
147.
Ramer, M. S., Kawaja, M. D., Henderson, J. T., Roder, J. C., & Bisby, M. A. (1998). Glial overexpression of NGF enhances neuropathic pain and adrenergic sprouting into DRG following chronic sciatic constriction in mice. Neuroscience Letters, 251, 53-56.
148.
Rego, A. C., & Oliveira, C. R. (2003). Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochemical Research, 28, 1563-1574.
149.
Regulier, E., de Almeida, L. P., Sommer, B., Aebischer, P., & Deglon, N. (2002). Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentaviral vectors in the quiniolinic acid rat model of Huntington's disease. Human Gene Therapy, 13, 1981-1990.
150.
Reiser, J., Zhang, X. Y., Hemenway, C. S., Mondal, D., Pradhan, L., & La Russa, V. F. (2005). Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opinion in Biological Therapy, 5, 1571-1584.
151.
Roos, R. A. C., Vegter-van der Vlis, M., & Hermans, J. (1991). Age at onset in Huntington's disease: Effect of line of inheritance and patient's sex. Journal of Medical Genetics, 28, 515-519.
152.
Russell, D. S., & Duman, R. S. (2002). Neurotrophic factors and intracellular signal transduction pathways. In K. L. Davis, D. S. Charney, J. T. Coyle, & C. B. Nemeroff (Eds.), Neuropsychopharmacology: The fifth generation of progress (pp. 207-215). Nashville, TN: American College of Neuropsychopharmacology.
153.
Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005). Mesenchymal stem cells avoid allogeneic rejection. Journal of Inflammation (London), 26, 2-8.
154.
Ryu, J. K., Kim, J., Cho, S. J., Hatori, K., Nagai, A., Choi, H. B., et al. (2004). Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiology of Disease, 16, 68-77.
155.
Sabel, B. A., Delmastro, R., Dunbar, G. L., & Stein, D. G. (1987). GM1 ganglioside reduces anterograde degeneration in brain damaged rats. Neuroscience Letters, 77, 360-366.
156.
Sabel, B. A., Dunbar, G. L., Butler, W. M., & Stein, D. G. (1985). GM1 gangliosides stimulate neuronal reorganization and reduce rotational asymmetry after hemitransections of the nigrostriatal pathway. Experimental Brain Research, 60, 27-37.
157.
Sabel, B. A., Dunbar, G. L., & Stein, D. G. (1984). Gangliosides minimize behavioral deficits and enhance structural repair after brain injury. Journal of Neuroscience Research, 12, 429-443.
158.
Sabel, B. A., Slavin, M. D., & Stein, D. G. (1984). GM1 ganglioside treatment facilitates behavioral recovery from bilateral brain damage. Science, 225, 340-342.
159.
Sakai, T., Johnson, K. J., Murozono, M., Sakai, K., Magnuson, M. A., Wieloch, T., et al. (2001). Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis. Nature Medicine, 7, 324-330.
160.
Samano, V., Styles, V. L., & Chan, J. H. (2000). An improved synthesis of 2-amino-5-[(4-chlorophphenyl)thio]-4-morpholinopyrimidine (BW394U): A potential antisenility agent. Journal of Heterocyclic Chemistry, 37, 183-186.
161.
Sanchez-Ramos, J., Song, S., Cardozo-Pelaez, F., Hazzi, C., Stedeford, T., Willing, A., et al. (2000). Adult bone marrow stromal cells differentiate into neural cells in vitro. Experimental Neurology, 164, 247-256.
162.
Schumacher, J. M., Short, M. P., Hyman, B. T., Breakefield, X. O., & Isacson, O. (1991). Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience, 45, 561-570.
163.
Schwarz, E. J., Alexander, G. M., Prockop, D. J., & Azizi, S. A. (1999). Multipotential marrow stromal cells transduced to produce LDOPA: Engraftment in a rat model of Parkinson disease. Human Gene Therapy, 10, 2539-2549.
164.
Seki, M., Nawa, H., Fukuchi, T., Abe, H., & Takei, N. (2003). BDNF is upregulated by postnatal development and visual experience: Quantitative and immunohistochemical analysis of BDNF in the rat retina. Investigative Opthalmology & Visual Science, 44, 3211-3218.
165.
Sendtner, M. (1998). Neurotrophic factors: Effects in modulating properties of the neuromuscular endplate. Cytokine & Growth Factor Reviews, 9, 1-7.
166.
Seniuk-Tatton, N. A., Henderson, J. T., & Roder, J. C. (1995). Neurons express ciliary neurotrophic factor mRNA in the early postnatal and adult rat brain. Journal of Neuroscience Research, 41, 663-676.
167.
Shear, D. A., Dong, J., Gundy, C. D., Haik-Creguer, K. L., & Dunbar, G. L. (1998). Comparison of intrastriatal injections of quinolinic acid and 3-nitroproprionic acid for use in animal models of Huntington's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 22, 1217-1240.
168.
Shear, D. A., Dong, J., Haik-Creguer, K. L., Bazzett, T. J., Albin, R. L., & Dunbar, G. L. (1998). Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task. Experimental Neurology, 150, 305-311.
169.
Shear, D. A., Haik, K. L., & Dunbar, G. L. (2000). Creatine reduces 3-nitropropionic-acid-induced cognitive and motor abnormalities in rats. NeuroReport, 11, 1833-1837.
170.
Sieradzan, K. A., & Mann, D. M. (2001). The selective vulnerability of nerve cells in Huntington's disease. Neuropathology and Applied Neurobiology, 27, 1-21.
171.
Smith, R., Brundin, P., & Li, J.-Y. (2005). Synaptic dysfunction in Huntington's disease: A new perspective. Cellular and Molecular Life Sciences, 62, 1901-1912.
172.
Spires, T. L., Grote, H. E., Varshney, N. K., Cordery, P. M., van Dellen, A., Blakemore, C., et al. (2004). Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. Journal of Neuroscience, 24, 2270-2276.
173.
Stack, E. C., Kubilus, J. K., Smith, K., Cormier, K., Del Signore, S. J., Guelin, E., et al. (2005). Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. Journal of Comparative Neurology, 490, 354-370.
174.
Stein, D. G., Brailowsky, S., & Will, B. (1995). Brain repair. New York: Oxford University Press.
175.
Stockli, K. A., Lillien, L. E., Naher-Noe, M., Breitfeld, G., Hughes, R. A., Raff, M. C., et al. (1991). Regional distribution, developmental changes, and cellular localization of CNTF-mRNA and protein in the rat brain. Journal of Cell Biology, 115, 447-459.
176.
Stucky, C. L., Shin, J.-B., & Lewin, G. R. (2002). Neurotrophin-4: A survival factor for adult sensory neurons. Current Biology, 12, 1401-1404.
177.
Tanaka, T., Saito, H., & Matsuki, N. (1997). Inhibition of GABAA synaptic responses by brain-derived neurotrophic factor (BDNF) in rat hippocampus. Journal of Neuroscience, 17, 2959-2966.
178.
Taniguchi, F., Harada, T., Deura, I., Iwabe, T., Tsukihara, S., & Terakawa, N. (2004). Hepatocyte growth factor promotes cell proliferation and inhibits progesterone secretion via PKA and MAPK pathways in a human granulosa cell line. Molecular and Reproductive Development, 68, 335-344.
179.
Toffano, G., Savoini, G. E., Moroni, F., Lombardi, G., Calza, L., & Agnati, L. F. (1983). GM1 gangliosides stimulate the regeneration of dopaminergic neurons in the central nervous system. Brain Research, 261, 163-166.
180.
Toffano, G., Savoini, G. E., Moroni, F., Lombardi, G., Calza, L., & Agnati, L. F. (1984). Chronic GM1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat. Brain Research, 296, 233-239.
181.
Torasdotter, M., Metsis, M., Henriksson, B., Winblad, B., & Mohammed, A. H. (1998). Environmental enrichment results in higher levels of nerve growth factor mRNA in the rat visual cortex and hippocampus. Behavioral Brain Research, 93, 83-90.
182.
Vaccarino, F. M., Schwartz, M. L., Hartigan, D., & Leckman, J. F. (1995). Basic fibroblast growth factor increases the number of excitatory neurons containing glutamate in the cerebral cortex. Cerebral Cortex, 5, 64-78.
183.
Van Raamsdonk, J. M., Pearson, J., Slow, E. J., Hossain, S. M., Leavitt, B. R., & Hayden, M. R. (2005). Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. Journal of Neuroscience, 25, 4169-4180.
184.
Varon, S., Raiborn, C., & Norr, S. (1974). Association of antibody to nerve growth factor with ganglionic non-neurons (glia) and consequent interference with their neuron-supportive action. Experimental Cell Research, 88, 247-256.
185.
Vila, M., & Przedborski, S. (2003). Targeting programmed cell death in neurodegenerative diseases. Nature Reviews Neuroscience, 4, 365-375.
186.
Vonsattel, J.-P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. G., & Richardson, E. P., Jr. (1985). Neuropathological classification of Huntington's disease. Journal of Neuropathology and Experimental Neurology, 44, 559-577.
187.
Weimar, I. S., Miranda, N., Muller, E. J., Hekman, A., Kerst, J. M., de Gast, G. C., et al. (1998). Hepatocyte growth factor/scatter factor (HGF/SF) is produced by human bone marrow stromal cells and promotes proliferation, adhesion and survival of human hematopoietic progenitor cells (CD34+). Experimental Hematology, 26, 885-894.
188.
Widmer, H. R., & Hefti, F. (1994). Stimulation of GABAergic neuron differentiation by NT-4/5 in cultures of rat cerebral cortex. Developmental Brain Research, 80, 279-284.
189.
Xu, B., Zang, K., Ruff, N. L., Zhang, Y. A., McConnell, S. K., Stryker, M. P., et al. (2000). Cortical degeneration in the absence of neurtrophin signaling: Dendritic retraction and neuronal loss after removal of the receptor TrkB. Neuron, 26, 233-245.
190.
Yin, Q., Kemp, G. J., & Frostick, S. P. (1998). Neurotrophins, neurones, and peripheral nerve regeneration. Journal of Hand Surgery (Edinburgh, Lothian), 23, 433-437.
191.
Zeron, M. M., Chen, N., Moshaver, A., Lee, A. T., Wellington, C. L., Hayden, M. R., et al. (2001). Mutant huntingtin enhances excitotoxic cell death. Molecular & Cellular Neurosciences, 17, 41-53.
192.
Zeron, M. M., Fernandes, H. B., Krebs, C., Shehadeh, J., Wellington, C. L., Leavitt, B. R., et al. (2004). Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Molecular & Cellular Neurosciences, 25, 468-479.
193.
Zhao, L. R., Duan, W. M., Reyes, M., Keene, C. D., Verfaillie, C. M., & Low, W. C. (2002). Human bone marrow stem cells exhibit neural phenotypes and ameliorate neurological deficits after grafting into the ischemic brain of rats. Experimental Neurology, 174, 11-20.
194.
Zhou, X. F., & Rush, R. A. (1994). Localization of neurotrophin-3-like immunoreactivity in the rat central nervous system. Brain Research, 643, 162-172.
195.
Zihlmann, K. B., Ducray, A. D., Schaller, B., Huber, A. W., Krebs, S. H., Andres, R. H., et al. (2005). The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons. Brain Research Bulletin, 68, 42-53.
